vs
艾伯维（ABBV）与NATIONAL HEALTHCARE CORP（NHC）财务数据对比。点击上方公司名可切换其他公司
艾伯维的季度营收约是NATIONAL HEALTHCARE CORP的43.0倍（$16.6B vs $386.5M）。艾伯维净利率更高（10.9% vs 6.4%，领先4.5%）。艾伯维同比增速更快（10.0% vs 4.6%）。艾伯维自由现金流更多（$4.9B vs $6.4M）。过去两年艾伯维的营收复合增速更高（16.2% vs 14.0%）
艾伯维是一家总部位于美国伊利诺伊州北芝加哥的制药企业，专注于研发、生产覆盖多种疾病领域的治疗药物，致力于为全球各地患者提供安全有效的临床解决方案，在全球医药行业拥有较高的知名度与影响力。
HCA Healthcare是1968年成立的美国营利性医疗服务运营商，总部位于田纳西州纳什维尔。截至2020年5月，该公司在全美20个州及英国持有并运营186家医院，还有约2400个医疗服务网点，涵盖手术中心、独立急诊室、紧急护理中心及医师诊所，2024年位列美国财富500强第61位。
ABBV vs NHC — 直观对比
营收规模更大
ABBV
是对方的43.0倍
$386.5M
营收增速更快
ABBV
高出5.4%
4.6%
净利率更高
ABBV
高出4.5%
6.4%
自由现金流更多
ABBV
多$4.9B
$6.4M
两年增速更快
ABBV
近两年复合增速
14.0%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $16.6B | $386.5M |
| 净利润 | $1.8B | $24.8M |
| 毛利率 | 72.6% | — |
| 营业利润率 | 27.3% | 8.6% |
| 净利率 | 10.9% | 6.4% |
| 营收同比 | 10.0% | 4.6% |
| 净利润同比 | 8354.5% | 308.6% |
| 每股收益（稀释后） | $1.02 | $1.58 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABBVNHC
| Q4 25 | $16.6B | $386.5M | ||
| Q3 25 | $15.8B | $382.7M | ||
| Q2 25 | $15.4B | $374.9M | ||
| Q1 25 | $13.3B | $373.7M | ||
| Q4 24 | $15.1B | $369.4M | ||
| Q3 24 | $14.5B | $340.2M | ||
| Q2 24 | $14.5B | $300.7M | ||
| Q1 24 | $12.3B | $297.2M |
净利润ABBVNHC
| Q4 25 | $1.8B | $24.8M | ||
| Q3 25 | $186.0M | $39.2M | ||
| Q2 25 | $938.0M | $23.7M | ||
| Q1 25 | $1.3B | $32.2M | ||
| Q4 24 | $-22.0M | $6.1M | ||
| Q3 24 | $1.6B | $42.8M | ||
| Q2 24 | $1.4B | $26.8M | ||
| Q1 24 | $1.4B | $26.2M |
毛利率ABBVNHC
| Q4 25 | 72.6% | — | ||
| Q3 25 | 66.4% | — | ||
| Q2 25 | 71.8% | — | ||
| Q1 25 | 70.0% | — | ||
| Q4 24 | 70.9% | — | ||
| Q3 24 | 70.9% | — | ||
| Q2 24 | 70.9% | — | ||
| Q1 24 | 66.7% | — |
营业利润率ABBVNHC
| Q4 25 | 27.3% | 8.6% | ||
| Q3 25 | 12.1% | 7.9% | ||
| Q2 25 | 31.7% | 9.1% | ||
| Q1 25 | 28.0% | 8.2% | ||
| Q4 24 | -9.9% | 7.8% | ||
| Q3 24 | 26.5% | 6.7% | ||
| Q2 24 | 27.6% | 7.5% | ||
| Q1 24 | 22.7% | 5.3% |
净利率ABBVNHC
| Q4 25 | 10.9% | 6.4% | ||
| Q3 25 | 1.2% | 10.3% | ||
| Q2 25 | 6.1% | 6.3% | ||
| Q1 25 | 9.6% | 8.6% | ||
| Q4 24 | -0.1% | 1.6% | ||
| Q3 24 | 10.8% | 12.6% | ||
| Q2 24 | 9.5% | 8.9% | ||
| Q1 24 | 11.1% | 8.8% |
每股收益（稀释后）ABBVNHC
| Q4 25 | $1.02 | $1.58 | ||
| Q3 25 | $0.10 | $2.50 | ||
| Q2 25 | $0.52 | $1.52 | ||
| Q1 25 | $0.72 | $2.07 | ||
| Q4 24 | $-0.03 | $0.38 | ||
| Q3 24 | $0.88 | $2.73 | ||
| Q2 24 | $0.77 | $1.73 | ||
| Q1 24 | $0.77 | $1.69 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $5.3B | $92.8M |
| 总债务越低越好 | $58.9B | $40.0M |
| 股东权益账面价值 | $-3.3B | $1.1B |
| 总资产 | $134.0B | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.04× |
8季度趋势，按日历期对齐
现金及短期投资ABBVNHC
| Q4 25 | $5.3B | $92.8M | ||
| Q3 25 | $5.7B | $130.6M | ||
| Q2 25 | $6.5B | $111.0M | ||
| Q1 25 | $5.2B | $90.4M | ||
| Q4 24 | $5.6B | $76.1M | ||
| Q3 24 | $7.3B | $84.8M | ||
| Q2 24 | $13.2B | $136.2M | ||
| Q1 24 | $18.1B | $94.0M |
总债务ABBVNHC
| Q4 25 | $58.9B | $40.0M | ||
| Q3 25 | $63.0B | $73.1M | ||
| Q2 25 | $63.0B | $110.0M | ||
| Q1 25 | $64.5B | $134.0M | ||
| Q4 24 | $60.3B | $137.0M | ||
| Q3 24 | $58.5B | $147.0M | ||
| Q2 24 | $58.0B | — | ||
| Q1 24 | $63.8B | — |
股东权益ABBVNHC
| Q4 25 | $-3.3B | $1.1B | ||
| Q3 25 | $-2.6B | $1.1B | ||
| Q2 25 | $-183.0M | $1.0B | ||
| Q1 25 | $1.4B | $1.0B | ||
| Q4 24 | $3.3B | $980.2M | ||
| Q3 24 | $6.0B | $983.5M | ||
| Q2 24 | $6.8B | $945.8M | ||
| Q1 24 | $8.0B | $924.7M |
总资产ABBVNHC
| Q4 25 | $134.0B | $1.5B | ||
| Q3 25 | $133.9B | $1.6B | ||
| Q2 25 | $137.2B | $1.6B | ||
| Q1 25 | $136.2B | $1.5B | ||
| Q4 24 | $135.2B | $1.5B | ||
| Q3 24 | $143.4B | $1.6B | ||
| Q2 24 | $141.9B | $1.3B | ||
| Q1 24 | $148.9B | $1.3B |
负债/权益比ABBVNHC
| Q4 25 | — | 0.04× | ||
| Q3 25 | — | 0.07× | ||
| Q2 25 | — | 0.11× | ||
| Q1 25 | 45.44× | 0.13× | ||
| Q4 24 | 18.15× | 0.14× | ||
| Q3 24 | 9.70× | 0.15× | ||
| Q2 24 | 8.56× | — | ||
| Q1 24 | 7.97× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $5.2B | $16.8M |
| 自由现金流经营现金流 - 资本支出 | $4.9B | $6.4M |
| 自由现金流率自由现金流/营收 | 29.4% | 1.7% |
| 资本支出强度资本支出/营收 | 2.0% | 2.7% |
| 现金转化率经营现金流/净利润 | 2.87× | 0.68× |
| 过去12个月自由现金流最近4个季度 | $17.8B | $148.6M |
8季度趋势，按日历期对齐
经营现金流ABBVNHC
| Q4 25 | $5.2B | $16.8M | ||
| Q3 25 | $7.0B | $66.2M | ||
| Q2 25 | $5.2B | $62.8M | ||
| Q1 25 | $1.6B | $39.3M | ||
| Q4 24 | $7.0B | $12.8M | ||
| Q3 24 | $5.4B | $34.2M | ||
| Q2 24 | $2.3B | $50.7M | ||
| Q1 24 | $4.0B | $9.6M |
自由现金流ABBVNHC
| Q4 25 | $4.9B | $6.4M | ||
| Q3 25 | $6.6B | $56.5M | ||
| Q2 25 | $4.9B | $52.6M | ||
| Q1 25 | $1.4B | $33.1M | ||
| Q4 24 | $6.8B | $4.6M | ||
| Q3 24 | $5.2B | $28.6M | ||
| Q2 24 | $2.0B | $42.8M | ||
| Q1 24 | $3.8B | $3.7M |
自由现金流率ABBVNHC
| Q4 25 | 29.4% | 1.7% | ||
| Q3 25 | 42.1% | 14.8% | ||
| Q2 25 | 31.7% | 14.0% | ||
| Q1 25 | 10.5% | 8.9% | ||
| Q4 24 | 44.7% | 1.3% | ||
| Q3 24 | 35.9% | 8.4% | ||
| Q2 24 | 14.0% | 14.2% | ||
| Q1 24 | 31.3% | 1.2% |
资本支出强度ABBVNHC
| Q4 25 | 2.0% | 2.7% | ||
| Q3 25 | 2.4% | 2.5% | ||
| Q2 25 | 1.7% | 2.7% | ||
| Q1 25 | 1.8% | 1.6% | ||
| Q4 24 | 1.9% | 2.2% | ||
| Q3 24 | 1.7% | 1.7% | ||
| Q2 24 | 1.7% | 2.6% | ||
| Q1 24 | 1.6% | 2.0% |
现金转化率ABBVNHC
| Q4 25 | 2.87× | 0.68× | ||
| Q3 25 | 37.76× | 1.69× | ||
| Q2 25 | 5.49× | 2.65× | ||
| Q1 25 | 1.27× | 1.22× | ||
| Q4 24 | — | 2.10× | ||
| Q3 24 | 3.49× | 0.80× | ||
| Q2 24 | 1.66× | 1.89× | ||
| Q1 24 | 2.95× | 0.37× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ABBV
暂无分部数据
NHC
| Inpatient Services Segment | $333.7M | 86% |
| Homecare Services Segment | $40.0M | 10% |
| Other | $11.2M | 3% |
| National | $1.6M | 0% |
